Tesamorelin
Price on application
Tesamorelin is a stabilized synthetic analog of GHRH with a trans-3-hexenoic acid modification. It is the only GHRH analog FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy.
Research Profile
Tesamorelin is a modified form of GHRH (1-44) with a trans-3-hexenoic acid group attached to the tyrosine residue, enhancing its stability and biological activity. As a GHRH analog, it stimulates pituitary GH synthesis and release through the natural GHRH receptor pathway. Clinical trials demonstrated significant reductions in visceral adipose tissue, improvements in lipid profiles, and increases in IGF-1 levels. Tesamorelin received FDA approval in 2010 for the treatment of HIV-associated lipodystrophy, making it one of the few peptides with regulatory approval for a metabolic indication.
Technical Details
- Chemical Formula
- C221H366N72O67S
- Synonyms
- Tesamorelin Acetate, Egrifta, TH9507
- Molecular Weight
- 5135.89 g/mol
- CAS Number
- 218949-48-5
- Appearance
- Lyophilized White Powder
- Purity
- >98% (HPLC Verified)
- Shelf Life
- 36 months (Store at -20°C)